Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Arthritis & Rheumatology

Topics

Medicine

Immunology

Pathology

Internal Medicine

Urology

Show all topics

DOI

10.1002/art.42926

License

CC-BY-NC-ND

Other Formats

PDF